On Aug. 29, 2022, the U.S. Department of Health and Human Services announced it had provided approximately $11 million to support the first U.S.-based fill and finish manufacturing of JYNNEOS ﾖ a vaccine approved to prevent smallpox and monkeypox ﾖ at Grand River Aseptic Manufacturing (GRAM) in Grand Rapids, Michigan.

On August 18, Bavarian Nordic, maker of JYNNEOS, and GRAM announced an agreement to establish this first U.S.-based fill and finish capability for the JYNNEOS vaccine, an agreement facilitated by BARDA.